Gemcitabine and carboplatin combination chemotherapy for 27 cases of advanced non-small-cell lung cancer
- VernacularTitle:吉西他滨加卡铂治疗晚期非小细胞肺癌
- Author:
Juan YAO
;
Mei XU
;
Shujuan LIU
- Publication Type:Journal Article
- Keywords:
lung neoplasm;
advanced non-small-cell lung cancer;
gemcitabine;
carboplatin;
combination chemotherapy
- From:China Oncology
1998;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To evaluate the short-term effects and toxic side-effects of GEM plus CBP combination chemotherapy in treating advanced non-small-cell lung cancer(NSCLC). Methods:27 patients with grades Ⅲ and Ⅳ NSCLC(10 naive cases,17 retreated chemotherapy cases received Gemcitabine 1 250 mg/m 2 ,iv drip d 1.8,and carboplatin 300 mg/m 2 in the first day. Results:There were 6 CR+PR cases in naive patients,the overall response rate(OR)was 60.0%,iv drip 7 of retreated chemotherapy cases were CR+PR,the OR was 41.2%. The OR of both group patients was 44.4%.The main toxic side-effects of the patients were marrow-suppression. Conclusions:The combination chemotherapy of gemcitabine plus carboplatin was effective for advanced NSCLC and the toxicities were well tolerated.
